Price records re-read October 15, 2026 on providers’ own pages · Methodology v4.1 · Medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP · Corrections log
Between September 15 and October 15, 2026, the developments that matter most for cash-pay GLP-1 patients were FDA’s warning letter to Empower Pharmacy, the counterfeit Ozempic charges, FDA’s updated GLP-1 page, Rhode Island Medicaid’s weight-loss coverage cut and the Medicare GLP-1 Bridge extension.
12 dated entries, newest first. “Reported” means news reporting we could not confirm on a primary page.
· confirmed
Our October re-read: prices checked on providers’ own pages
We re-read the pricing pages of the programs in this index on October 15, 2026. Eden now lists compounded tirzepatide at $129 and semaglutide at $99 a month with no membership fee; Sprout Health and Found now bill every 4 weeks; Henry Meds and Mochi Health no longer print a compounded price on the pages we read; several sites could not be read and keep their August figures, marked "not re-read".
What it means for cash-pay patients: Compare programs on the October figures in the price database; older rows are dated and are not used in computed rankings.
Lilly sets October 29 for third-quarter results; Medicare Open Enrollment opens
Eli Lilly said it will announce third-quarter 2026 results on October 29, 2026. Medicare Open Enrollment runs October 15 to December 7, with changes taking effect January 1.
What it means for cash-pay patients: Watch October 29 for any change to Zepbound or Foundayo self-pay terms; Lilly’s Zepbound savings-card terms end December 31, 2026; we found no end date for the self-pay prices.
No final FDA decision on the 503B bulks list for GLP-1s
FDA proposed (announced April 30, 2026; 91 FR 23431) not to place tirzepatide, semaglutide or liraglutide on the 503B bulks list; the comment period closed July 30, 2026 (91 FR 38719). We found no final decision as of October 15, 2026.
What it means for cash-pay patients: Nothing has changed yet for programs filled by 503A pharmacies; a final rule would mainly affect 503B outsourcing facilities.
Walmart to cover Ozempic and Mounjaro for employees with type 2 diabetes in 2027 (CNBC)
CNBC reported on October 13, 2026 that Walmart will cover more than 250 prescriptions at no cost to employees in 2027, including Ozempic and Mounjaro for type 2 diabetes after a new prior authorization. The report says Walmart still does not cover GLP-1s for weight loss. These details come from news reporting, not a Walmart plan document.
What it means for cash-pay patients: Employees who want a GLP-1 for weight loss stay in the cash-pay market.
Mochi Health’s per-dose compounded pricing covered in the press
Mochi Health’s own blog post on per-dose pricing (first published August 2026, updated September 18, 2026) says compounded semaglutide runs $60-$99 and tirzepatide $90-$199 a month by dose, with membership billed separately. Its weight-loss page read on October 15 prints brand prices but no compounded price.
What it means for cash-pay patients: Entry doses cost less than before; at higher doses the price is the old flat rate plus membership. Mochi is shown as "no price printed" in our index until its program page prints one.
FDA posts warning letters to two websites selling unapproved semaglutide
The FDA posted warning letters 737806 (onlinegenericmedicine.com, dated September 23) and 737810 (cheapmedicineshop.com, dated September 24) on October 6, 2026. Both concern unapproved, misbranded injectable semaglutide sold online.
What it means for cash-pay patients: "Generic semaglutide" sold online without a prescription is not a legitimate low-cost option.
FDA updates its page on unapproved GLP-1 drugs used for weight loss
FDA’s "Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" page (current as of October 1, 2026) lists telehealth red flags, gives a 28-day discard rule for compounded multi-dose GLP-1 vials, says retatrutide and cagrilintide cannot be used in compounding under federal law, and reports 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026.
What it means for cash-pay patients: Ask how many weeks a vial is meant to last; a vial meant for more than 28 days conflicts with FDA’s guidance.
Rhode Island Medicaid stops covering GLP-1s prescribed only for weight loss
Effective October 1, 2026, Rhode Island Medicaid no longer covers Foundayo, Saxenda, Wegovy and Zepbound prescribed solely for weight loss, according to a Tufts Health RITogether provider notice. Coverage continues for type 2 diabetes and other FDA-approved indications.
What it means for cash-pay patients: Affected members must pay cash (LillyDirect, NovoCare or a telehealth program) or stop treatment; see our Rhode Island Medicaid page. Rhode Island Medicaid and GLP-1s →
Two men charged over counterfeit Ozempic sold into the U.S.
The Justice Department and FDA announced charges against Swapnadip Roy and Vicky Ramancha, accused of distributing counterfeit Ozempic from China between July 2023 and April 2024, including after FDA’s December 2023 seizure and warning. An indictment is an allegation; both are presumed innocent.
What it means for cash-pay patients: Fill brand GLP-1s through a state-licensed pharmacy you can name. Our article →
CMS: Medicare GLP-1 Bridge extended through December 31, 2027
CMS’s BALANCE model page (modified September 29, 2026) says the Medicare GLP-1 Bridge has been extended through December 31, 2027, and includes an FAQ about "the BALANCE Model not launching in Medicare in 2027." Per Medicare.gov, the Bridge ($50 a month) covers Foundayo, Wegovy and the Zepbound KwikPen for eligible Part D enrollees by BMI and listed conditions; people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge, though their Part D plan "might cover" a GLP-1.
What it means for cash-pay patients: Medicare enrollees should check Bridge eligibility before paying cash.
FDA warning letter to Empower Pharmacy over compounded tirzepatide and semaglutide
FDA warning letter 738238, dated September 18 and posted September 22, 2026, says Empower Pharmacy’s compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin products "appear to be essentially copies of FDA-approved semaglutide and tirzepatide products" and cites insanitary conditions.
What it means for cash-pay patients: Ask which pharmacy fills your prescription and check it against FDA’s warning-letter index. Empower Pharmacy and GLP-1s →
Novo Nordisk: about 90% of Wegovy pill prescriptions are self-pay
Novo Nordisk’s U.S. capital markets day deck (September 21, 2026) says the Wegovy pill has passed 7 million prescriptions this year, about 90% of them self-pay, and describes partnerships with "9+ telehealth entities".
What it means for cash-pay patients: Expect continued self-pay offers through NovoCare and telehealth partners; NovoCare lists the pill at $149 to $299 a month by dose.